« Back
Home /
Biotinylated Human B7-H6 / NCR3LG1 Protein, His,Avitag™

Biotinylated Human B7-H6 / NCR3LG1 Protein, His,Avitag™

Item no.	B76-H82E5-200ug
Manufacturer	ACROBiosystems
Amount	200 ug
Quantity options	200 ug 25 ug
Category	Peptides & Proteins Recombinant Proteins
Type	Proteins Recombinant
Format	Solid
Specific against	Human (Homo sapiens)
Host	HEK293
Conjugate/Tag	Biotin, Avi
Purity	90%
Citations	(1) Wu MR, et all., 2015, Gene Ther. 22(8):675-84. (2) Phillips M, et all., 2016, Biopolymers. 106(5):658-72. (3) Flajnik MF, et all., 2012 Immunogenetics. 64(8):571-90.
NCBI	NP 001189368.1
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	B7-H6,NCR3LG1,B7 Homolog 6
Shipping Condition	Room temperature
Available
Manufacturer - Category	Protein
Manufacturer - Conjugate / Tag	C-10xHis & C-Avi, Biotin-labeled
Shipping Temperature	RT
Storage Conditions	-20°C
Molecular Weight	30.4 kDa
Manufacturer - Format	Powder
Description	The B7 family of genes is essential in the regulation of the adaptive immune system. one of which is the recently discovered B7H6. Humans and rats have a single B7H6 gene; however, many B7H6 genes were detected in a single large cluster in the Xenopus genome. Chimeric antigen receptor (CAR) T-cell therapies have demonstrated durable and potentially curative therapeutic efficacy against B-cell leukemia in clinical trials. In this study, B7H6, a ligand for the NK cell activating receptor NKp30, was targeted to create a CAR that targets multiple tumor types. B7H6 is expressed on various primary human tumors, including leukemia, lymphoma and gastrointestinal stromal tumors, but it is not constitutively expressed on normal tissues.
Background	The B7 family of genes is essential in the regulation of the adaptive immune system. one of which is the recently discovered B7H6. Humans and rats have a single B7H6 gene; however, many B7H6 genes were detected in a single large cluster in the Xenopus genome. Chimeric antigen receptor (CAR) T-cell therapies have demonstrated durable and potentially curative therapeutic efficacy against B-cell leukemia in clinical trials. In this study, B7H6, a ligand for the NK cell activating receptor NKp30, was targeted to create a CAR that targets multiple tumor types. B7H6 is expressed on various primary human tumors, including leukemia, lymphoma and gastrointestinal stromal tumors, but it is not constitutively expressed on normal tissues.
Molecule	B7-H6
Exp Region	Asp 25 - Ser 262
Characteristics	This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™). The protein has a calculated MW of 30.4 kDa. The protein migrates as 40-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin	1.0 EU per μg
Buffer	PBS, pH7.4
Stability	● -20°C to -70°C for 12 months in lyophilized state ● -70°C for 3 months under sterile conditions after reconstitution._x000D_For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Protectant	trehalose

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

B76-H82E5-200ug-datasheet.pdf

B76-H82E5-200ug-safety-datasheet.pdf